Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Asacol Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01469637
View directory record Official record
Conditions
Healthy
Interventions
sulfamethoxazole + MMX placebo, Sulfamethoxazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

NCT00751699
View directory record Official record
Conditions
Healthy
Interventions
Asacol, Lialda
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01442688
View directory record Official record
Conditions
Healthy
Interventions
Amoxicillin + MMX placebo, Amoxicillin + MMX mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 15, 2026, 2:45 AM EDT
Withdrawn Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

NCT05316220
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 15, 2026, 2:45 AM EDT
Terminated Phase 4 Interventional Results available

Cimzia Versus Mesalamine for Crohn's Recurrence

NCT01696942
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cimzia, Mesalamine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Mesalamine 4 gm/60 mL Rectal Enema

NCT00840203
View directory record Official record
Conditions
Healthy
Interventions
Rowasa® 4 gm/60 mL Rectal Enema, Mesalamine 4 gm/60 mL Rectal Enema
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 15, 2026, 2:45 AM EDT
Terminated Phase 3 Interventional

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

NCT01038739
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalazine, Placebo
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Smyrna Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

NCT01860963
View directory record Official record
Conditions
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions
Anal Pap smear and HPV DNA testing
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Recurrence of Diverticulitis

NCT00545740
View directory record Official record
Conditions
Diverticulitis
Interventions
SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
46
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 4 Interventional

Asacol Dosing Study for Active Ulcerative Colitis

NCT00194818
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol (mesalamine)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2008 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis

NCT00343850
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol (mesalamine)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine Once-Daily, Mesalamine Twice-Daily
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
233
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

NCT03399903
View directory record Official record
Conditions
HIV-1-infection, Gut Inflammation
Interventions
Pentasa vs Align
Drug
Lead sponsor
AIDS Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Results available

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

NCT01577966
View directory record Official record
Conditions
Brain Tumor
Interventions
Sulfasalazine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Asacol Acute Diverticulitis(DIVA)Study

NCT00554099
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalamine, Probiotic, Placebo, Dietary Advice, Antibiotic for Diverticulitis
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years to 85 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Merced, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

NCT00577473
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
44
States / cities
Birmingham, Alabama • Anaheim, California • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis

NCT01130844
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
5 Years to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
6
States / cities
Little Rock, Arkansas • Anaheim, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Correlation of Mesalamine Pharmacokinetics With Local Availability

NCT01999400
View directory record Official record
Conditions
Local Drug Concentration in Gastrointestinal Tract
Interventions
Pentasa 500 mg capsule x 2 with 240 mL water; single dose, Apriso 375 mg capsule x 3 with 240 mL water; single dose, Lialda 1200 mg tablet x 1 with 240 mL water; single dose, Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 15, 2026, 2:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

NCT05119140
View directory record Official record
Conditions
Ulcerative Colitis (Disorder)
Interventions
Hydroxychloroquine, Mesalamine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 15, 2026, 2:45 AM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Results available

Dose Escalation and Remission (DEAR)

NCT00652145
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Naples, Florida • Winter Park, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 15, 2026, 2:45 AM EDT
Completed Phase 2Phase 3 Interventional

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

NCT00952952
View directory record Official record
Conditions
Microscopic Colitis, Diarrhea
Interventions
Mesalamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Sep 15, 2026, 2:45 AM EDT